Intuitive Surgical (ISRG) presents a compelling bullish thesis with a $142.5B market cap, trailing P/E of 48.76, EPS of $8.25, and robust 23% YoY revenue growth to $10.58B TTM alongside 18.8% quarterly earnings growth. The company's dominant position in robotic-assisted surgery supports premium valuation justified by 28.1% profit margins and strong returns on equity of 17.2%. Forward P/E of 38.76 signals continued earnings expansion as adoption accelerates.
Key catalysts include ongoing da Vinci system installations, expansion into new surgical procedures, and earnings momentum with 6 strong buy and 16 buy analyst ratings targeting $567.80. Growth drivers encompass rising minimally invasive surgery demand, international market penetration, and recurring revenue from instruments and services that now exceed 70% of total sales.
Risks center on elevated valuation (P/E 48.76 vs. sector averages), potential regulatory delays for next-gen platforms, and macro headwinds from hospital capital spending. These are mitigated by ISRG's technological moat, 89% institutional ownership, and proven ability to sustain 20%+ revenue growth through innovation and clinical evidence.
Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.
Get Deeper Analysis
Ask Theo anything about ISRG — earnings, valuation, technicals, or portfolio fit.
Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.
Fundamental Snapshot
Revenue
10.5821B
EBITDA
3.8856B
Gross Profit
7.0151B
Operating Margin
30.9%
Profit Margin
28.1%
ROE
17.2%
Book Value
$49.31
Beta
1.509
52-Wk High
$603.88
52-Wk Low
$414.3
Avg Volume
2.9907M
PEG Ratio
2.227
Trading Data
Open
$421.13
Previous Close
$418.61
Day Range
$417.55 – $430.85
Volume
2.2755M
Shares Outstanding
354.163M
Analyst Target
$567.8
Frequently Asked Questions
What is Intuitive Surgical's business model?
Intuitive Surgical develops and sells the da Vinci Surgical System for robotic-assisted minimally invasive procedures. Revenue comes primarily from system sales, recurring instrument and accessory sales, and service contracts, with TTM revenue of $10.58B and 28.1% profit margins.
Where does ISRG generate most of its revenue?
The majority of revenue is recurring from instruments, accessories, and services tied to the installed base of da Vinci systems. This model delivered 23% YoY revenue growth to $10.58B TTM with EPS of $8.25.
What are ISRG's key competitive advantages?
ISRG holds a dominant market position in robotic surgery with over 8,000 da Vinci systems installed worldwide. Its technological leadership, extensive clinical data, and high switching costs create a strong moat, reflected in a 48.76 trailing P/E and $142.5B market cap.
What are the main risks for ISRG investors?
Key risks include high valuation (forward P/E 38.76), competition from other surgical robotics firms, and potential regulatory or reimbursement hurdles. These are offset by 18.8% YoY earnings growth, 89% institutional ownership, and a $567.80 analyst target price.
What is the growth outlook for Intuitive Surgical?
ISRG is positioned for continued expansion through new procedure adoption and international markets. Analysts project sustained double-digit growth, supported by 23% recent revenue increases and a forward P/E of 38.76 implying earnings momentum.
